Cargando…
Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
PURPOSE: To review published evidence for a treatment interval extension to ≥12-weeks in neovascular macular degeneration treated with intravitreal Aflibercept. METHODS: A systematic search was performed in the NCBI/PubMed database to identify pro- and retrospective studies retrieved by the key term...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6650619/ https://www.ncbi.nlm.nih.gov/pubmed/31409968 http://dx.doi.org/10.2147/OPTH.S185756 |